Press Releases

Catawba Research Collaborates With Bingli Inc. to Make Patient Pre-Screening Easier for Participants and Sites

PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

PrecisionLife and Metrodora Institute are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases including Long COVID, ME/CFS, ALS, Sjögren's syndrome, and many more.

uMed helps Queen Mary University of London and University College London move closer to understanding Parkinson’s risk factors as first-of-its-kind study exceeds 10,000 participant milestone

uMed, the health and research technology company has played a crucial role in expanding the participant base of PREDICT-PD - a joint studybetween Queen Mary University of London and University College London (UCL), and funded by Parkinson’s UK investigating the onset and early stages of Parkinson's disease

Biofourmis Secures Four New Agreements with Top-20 Pharma on Strength of Platform for Digital Clinical Trials and Digital Biomarkers

Biofourmis Secures Four New Agreements with Top-20 Pharma on Strength of Platform for Digital Clinical Trials and Digital Biomarkers

Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies

Abzena launches LabZient™, an analytical platform accelerating antibody development timelines by combining predictive in-silico evaluation with laboratory methods. LabZient™ streamlines assessment, reduces costs, and enables early measurement of critical quality attributes. Fit-for-purpose across various antibody types, including mAbs and ADCs, LabZient™ enhances efficiency in biopharma development.

AES Clean Technology enhances cleanroom construction capabilities through new senior appointment

Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing

About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics completed Bio Campus I with Plant 4, offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 180KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. Samsung Biologics Media Contact Claire Kim, Head of Marketing Communications cair.kim@samsung.com About LegoChem Biosciences, Inc. LegoChem Biosciences (KOSDAQ: 141080) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll. Since its foundation in 2006, LCB has focused on researching and developing Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics, and anti-fibrotic based on proprietary platform technologies. For more information, visit LegoChem Biosciences, Inc. at https://www.legochembio.com/index.php?lang=e LegoChem Biosciences Media Contact Daeyoung Jeong, Team Leader of IR/BD jdy@legochembio.com

Alfa Chemistry Releases Carbomer Series Products for Cosmetics and Personal Care Products Manufacturing

CD Formulation Shows the Ability of Coated Microneedle Preparation Technology for Novel Drug Delivery

Alfa Chemistry Catalysts: Porphyrin Ligands, Phthalocyanine Ligands Are Newly Released for the Science Community

Game-Changing ‘Audit Trail Review’ Application Secures ACDM 2024 Awards Nomination for CluePoints

Game-Changing ‘Audit Trail Review’ Application Secures ACDM 2024 Awards Nomination for CluePoints RBQM Leader Shortlisted for Accolade for Innovation in the Management of Clinical Data

Azenta Launches the BioArc Ultra, a Breakthrough, Automated Solution for Efficient, Eco-Friendly Ultracold Sample Management

Azenta, Inc has announced the launch of the BioArc™ Ultra, a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance.

Quantify Research Opens New Office in Finland

Quantify Research has announced the opening of its new office today in Helsinki, Finland.

Showcase on lab automation instruments and consumables on display at SLAS2024 International Conference and Exhibition

Azenta Life Sciences has announced that it will display a range of productivity-enhancing consumables, instruments, and automated sample storage products at SLAS 2024 in Boston, USA from February 5 - 7.

Verisense Health Adopts Datavant’s Data Connectivity Platform to Expand its Digital Health Panel’s RWD Sources

Datavant’s privacy-preserving record linkage technology will allow Verisense Health’s digital health data to generate richer patient insights.

Bourne Partners Advises Clincierge on its Sale to Greenphire

Greenphire, a leading innovator in software solutions for streamlining clinical trials, proudly announces the acquisition of Clincierge, a premier provider of concierge travel and logistics support for patients participating in clinical trials. This strategic move is poised to revolutionize the landscape of clinical trial support services by integrating unparalleled patient care with cutting-edge technology.

Lindus Health Introduces Bespoke “All-In-One CRO for Digital Therapeutics” Solution to Companies in the Space Streamline Clinical Trials

Lindus Health Introduces Bespoke “All-In-One CRO for Digital Therapeutics” Solution to Companies in the Space Streamline Clinical Trials

Effortless Measurement of All Four NADs and Glutathione for Laboratories

NADMED has announced an innovative technology designed for effortless extracting and measuring all four NADs and two glutathiones.

Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults

Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology

Infinity Bio, Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. This platform offers unparalleled depth in immune system analysis, advancing immunology, virology, autoimmunity, and allergy research, providing new disease insights, and discovering new biomarkers and treatments. The MIPSA technology exploits recent advances in high throughput DNA sequencing and DNA synthesis, to create and analyze the most complete panels of immune targets available.